Literature DB >> 9847364

Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses.

L Selig1, J C Pages, V Tanchou, S Prévéral, C Berlioz-Torrent, L X Liu, L Erdtmann, J Darlix, R Benarous, S Benichou.   

Abstract

Vpr and Vpx proteins from human and simian immunodeficiency viruses (HIV and SIV) are incorporated into virions in quantities equivalent to those of the viral Gag proteins. We demonstrate here that Vpr and Vpx proteins from distinct lineages of primate lentiviruses were able to bind to their respective Gag precursors. The capacity of HIV type 1 (HIV-1) Vpr mutants to bind to Pr55(Gag) was correlated with their incorporation into virions. Molecular analysis of these interactions revealed that they required the C-terminal p6 domain of the Gag precursors. While the signal for HIV-1 Vpr binding lies in the leucine triplet repeat region of the p6 domain reported to be essential for incorporation, SIVsm Gag lacking the equivalent region still bound to SIVsm Vpr and Vpx, indicating that the determinants for Gag binding are located upstream of this region of the p6 domain. Binding to Gag cleavage products showed that HIV-1 Vpr interacted directly with the nucleocapsid protein (NC), whereas SIVsm Vpr and Vpx did not interact with NC but with the p6 protein. These results (i) reveal differences between HIV-1 and SIVsm for the p6 determinants required for Vpr and Vpx binding to Gag and (ii) suggest that HIV-1 Vpr and SIVsm Vpr and Vpx interact with distinct cleavage products of the precursor following proteolytic processing in the virions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9847364      PMCID: PMC103865     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  HIV accessory proteins: leading roles for the supporting cast.

Authors:  D Trono
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

2.  Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation.

Authors:  X J Yao; R A Subbramanian; N Rougeau; F Boisvert; D Bergeron; E A Cohen
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria.

Authors:  K S Steimer; J P Puma; M D Power; M A Powers; C George-Nascimento; J C Stephans; J A Levy; R Sanchez-Pescador; P A Luciw; P J Barr
Journal:  Virology       Date:  1986-04-15       Impact factor: 3.616

5.  Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.

Authors:  F Re; D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.

Authors:  E Kondo; F Mammano; E A Cohen; H G Göttlinger
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle.

Authors:  J B Jowett; V Planelles; B Poon; N P Shah; M L Chen; I S Chen
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation.

Authors:  S Mahalingam; S A Khan; R Murali; M A Jabbar; C E Monken; R G Collman; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

10.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.

Authors:  O Boussif; F Lezoualc'h; M A Zanta; M D Mergny; D Scherman; B Demeneix; J P Behr
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

View more
  66 in total

1.  Efficient DNA transfection mediated by the C-terminal domain of human immunodeficiency virus type 1 viral protein R.

Authors:  A Kichler; J C Pages; C Leborgne; S Druillennec; C Lenoir; D Coulaud; E Delain; E Le Cam; B P Roques; O Danos
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(betaTrCP) ubiquitin ligase.

Authors:  I Lassot; E Ségéral; C Berlioz-Torrent; H Durand; L Groussin; T Hai; R Benarous; F Margottin-Goguet
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging.

Authors:  Y Jenkins; P V Sanchez; B E Meyer; M H Malim
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag).

Authors:  Y Jenkins; O Pornillos; R L Rich; D G Myszka; W I Sundquist; M H Malim
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Molecular and functional basis for the scaffolding role of the p50/dynamitin subunit of the microtubule-associated dynactin complex.

Authors:  Guillaume Jacquot; Priscilla Maidou-Peindara; Serge Benichou
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

6.  Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.

Authors:  Ferdinand Roesch; Léa Richard; Réjane Rua; Françoise Porrot; Nicoletta Casartelli; Olivier Schwartz
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Authors:  Nadine Laguette; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

8.  Degradation of SAMHD1 by Vpx Is Independent of Uncoating.

Authors:  Paula Jáuregui; Eric C Logue; Megan L Schultz; Stephanie Fung; Nathaniel R Landau
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.

Authors:  Bärbel Schröfelbauer; Qin Yu; Samantha G Zeitlin; Nathaniel R Landau
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells.

Authors:  Caroline Goujon; Vanessa Arfi; Thomas Pertel; Jeremy Luban; Julia Lienard; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.